RxDoctor Payments Data

Kathleen Baldwin

Family · Bethlehem, PANPI 1487191045

Payments from drug & device makers

$864in general payments, 2019–2025

Across 22 payments — averaging $39.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$514
  • Novo Nordisk$125
  • Sequel Med Tech, LLC$87
  • Tandem Diabetes Care, Inc.$78
  • Abbott$38
  • Tolmar, Inc.$23

What the payments were for

  • Food & beverage$864100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$864 in reported general payments places this provider in the 70th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$79,223
Medicare patients
408
Services billed
1,201

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide246$406,276
JardianceEmpagliflozin396$405,620
TrulicityDulaglutide290$375,236
Tresiba Flextouch U-200Insulin Degludec77$128,108
Tresiba Flextouch U-100Insulin Degludec134$109,806
MounjaroTirzepatide68$88,311
JanuviaSitagliptin Phosphate76$83,790
Lantus SolostarInsulin Glargine,hum.Rec.Anlog460$81,903
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog134$79,515
FarxigaDapagliflozin Propanediol69$74,608
TradjentaLinagliptin73$67,105
Novolog FlexpenInsulin Aspart180$52,453
RybelsusSemaglutide35$51,159
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog37$42,197
Humalog Kwikpen U-100Insulin Lispro81$35,276

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$125$480,160347 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,717 family providers in Pennsylvania.

Other family in Bethlehem

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →